Contact Us

*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Date you started taking this drug:

Date you stopped taking this drug:

What dosage were you prescribed daily?

How frequently was patient monitored by prescribing physician?

If patient started or stopped Rezulin more than once, please describe when and why:

Was patient warned of risk of liver damage, liver failure or death as a result of taking Rezulin (trogitazone)?

During or since use of Rezulin, were any of the following conditions experienced, suspected or diagnosed?

If liver function testing has been performed, please list date and results:

Please list other medications taken in the past 5 years:

Has patient ever taken Actos or Avandia?

Please further describe side effects:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

US appeals court reinstates Rezulin suit vs Warner-Lambert

Oct 5, 2006 |

A federal appeals court on Thursday reinstated a lawsuit against Warner-Lambert Co. by a group of Michigan residents who claim they suffered injuries as a result of their use of the diabetes drug Rezulin.

In a ruling issued late Thursday, the 2nd Circuit Court of Appeals vacated a lower court's ruling that tossed out the case last year.

In February 2005, U.S. District Judge Lewis A. Kaplan in Manhattan threw out the lawsuit by the Michigan plaintiffs, citing a Michigan law that shields pharmaceutical companies from product liability claims unless there is evidence that the drug company misrepresented or withheld material information in obtaining approval for the drug from the U.S. Food and Drug Administration.

At the time, the judge found that the Michigan claims couldn't be distinguished from other state "fraud-on-the-FDA" claims that have previously found to be preempted by federal law.

On Thursday, the appellate court disagreed and remanded the case to the district court for further proceedings.
Warner-Lambert, which was acquired by Pfizer Inc. (PFE) in June 2000, pulled Rezulin from the market in March 2000 at the FDA's request. The FDA initially approved the drug in 1997.

A Pfizer spokesman didn't immediately have a comment late Thursday.

Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo